Ionis Pharmaceuticals (NASDAQ:IONS) announces that, based on positive Phase 2 data, GlaxoSmithKline (NYSE:GSK) has exercised its option to in-license its antisense candidates for chronic hepatitis B virus (HBV) infection.
Under the terms of the agreement, Ionis is eligible to receive a $25M license fee, up to $237M in milestones and tiered low double-digit royalties on net sales.
Glaxo will now take over all development, regulatory and commercialization activities and costs.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.